17/11/2015 Retrospective evaluation of tyrosine kinase inhibitor (TKI)-everolimus (eve) and/or TKI-eve-TKI sequences in metastatic renal cell carcinoma (mRCC): A Fr…

http://meetinglibrary.asco.org/content/123918-142 1/4

◀ VISIT ASCO.org

Alvaro Marin

SearchHome » Meeting Library » Abstracts » 2014 Genitourinary Cancers Symposium

Retrospective evaluation of tyrosine kinase inhibitor (TKI)-everolimus (eve) and/orTKI-eve-TKI sequences in metastatic renal cell carcinoma (mRCC): A French survey—The sector study.

Subcategory: Renal Cell Cancer

Category: Genitourinary Cancer

Meeting: 2014 Genitourinary Cancers Symposium

Session Type and Session Title: General Poster Session C: Renal Cancer

Abstract Number: 509

Citation: J Clin Oncol 32, 2014 (suppl 4; abstr 509)

Author(s): Stephane Oudard, Florence Joly, Lionnel Geoffrois, Brigitte Laguerre, Nadine Houede, Philippe Barthelemy, Marine Gross-Goupil, Vano Yann-Alexandre, Olivier Lucidarme, François Bidault, Nadia Kelkouli, Bernard Escudier; HEGP, OncologieMédicale, Paris, France; Centre François Baclesse, Caen, France; Centre Alexis VAUTRIN, Vandoeuvre-lès-Nancy, France;Centre Eugène Marquis, Rennes, France; CHU Nîmes, Nîmes, France; Hôpitaux Universitaires de Strasbourg, Strasbourg,France; CHU Bordeaux, Bordeaux, France; European Hospital Georges Pompidou, Paris, France; Pitie Salpetriere Hospital,Paris, France; Gustave Roussy, Villejuif, France; Novartis, Paris, France; Department of Medical Oncology, Institut GustaveRoussy, Villejuif, France

Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caretsymbol (^).

Abstract Disclosures

Abstract: 

Background: In the RECORD-1 study, only 22% of the mRCC patients (pts) received eve in pure 2nd line. Thus more data inreal world are needed. A retrospective French survey, on a large patient population, was designed to evaluate efficacy for thesequence TKI-eve and/or TKI-eve-TKI in mRCC. Methods: Between 10/08 and 10/12, 164 mRCC pts from 26 french centers,

17/11/2015 Retrospective evaluation of tyrosine kinase inhibitor (TKI)-everolimus (eve) and/or TKI-eve-TKI sequences in metastatic renal cell carcinoma (mRCC): A Fr…

http://meetinglibrary.asco.org/content/123918-142 2/4

who progressed on initial TKI and received eve as 2nd line were recorded. In these pts, 3rd line TKI was recorded. Primaryendpoint was Duration of Treatment (DT) of each sequence. Secondary endpoints were best radiological response for eveevaluated by 2 independent radiologists, tolerability, dose reduction, overall survival from the start of first TKI (OS). Patientscharacteristics: Amongst 164 pts, 144 pts with follow-up > 4 months since initiation of eve were evaluated, 59/144 pts receivedTKI-eve-TKI. Before eve initiation: median age was 65 yrs, most pts were male (70.3%), had clear cell histology (92.3%), hadreceived sunitinib as first TKI (94.4%). Main comorbidities were: hypertension (43.8%), diabetes (15.3%), andhypercholesterolemia (19.4%). At the time of eve initiation, MSKCC classification was good (24.4%), intermediate (61.5%) orpoor (14.1%). Results: median DT of eve was 4 months and 21% pts were treated >9 months with 2.9% PR and 67.6% SD bycentral review. Correlation between response to first TKI and eve was observed. Dose reduction of eve for toxicity was 23.2%.The most common toxicities (all grades) were: stomatitis (25.3%), PNI (13%), fatigue (40.7%), hyperglycemia (9.3%),hypercholesterolemia (17.3%) and hypertriglyceridemia (22.8%). Median duration of TKI-eve sequence was 18 months(IC95%: 15-20), and OS was 36 months (IC95%: 27-56). For TKI-eve-TKI sequence (59 pts), sorafenib was mostly used(76.3%) with dose reduction and clinical benefit rate of 26.7% and 42.2% respectively. Median DT and OS were 24 and 41months (IC95%: 19-29; 25-57) respectively. Conclusions: In real world experience, for mRCC pts receiving TKI-evesequence, median DT of eve is 4 months with OS of 36 months which compares favorably with RECORD1 and RECORD 3trials respectively.

Share This Page

ASSOCIATED POSTER

Abstracts by Stephane Oudard:

Abiraterone acetate in patients with metastatic castration-resistant prostate cancer: Long term outcome of theTemporary Authorization for Use program in France.Meeting: 2015 Genitourinary Cancers Symposium | Abstract No: 264 | First Author: Nadine HouedeCategory: Genitourinary Cancer - Prostate Cancer - Advanced Disease

Androgen deprivation therapy (ADT) plus docetaxel (D) versus ADT alone for hormone-naïve metastatic prostatecancer (PCa): Long-term analysis of the GETUG-AFU 15 phase III trial.Meeting: 2015 Genitourinary Cancers Symposium | Abstract No: 140 | First Author: Gwenaelle GravisCategory: Genitourinary Cancer - Prostate Cancer - Advanced Disease

Final analysis of COMET-1: Cabozantinib (Cabo) versus prednisone (Pred) in metastatic castration-resistantprostate cancer (mCRPC) patients (pts) previously treated with docetaxel (D) and abiraterone (A) and/orenzalutamide (E).Meeting: 2015 Genitourinary Cancers Symposium | Abstract No: 139 | First Author: Matthew Raymond SmithCategory: Genitourinary Cancer - Prostate Cancer - Advanced Disease

More

17/11/2015 Retrospective evaluation of tyrosine kinase inhibitor (TKI)-everolimus (eve) and/or TKI-eve-TKI sequences in metastatic renal cell carcinoma (mRCC): A Fr…

http://meetinglibrary.asco.org/content/123918-142 3/4

Meeting: 2014 Genitourinary Cancers SymposiumPresenter: Stephane Oudard

View Poster

HOME

ASCO-SEP

MOC

COURSE CATALOG

CERTIFICATES

TRAINING PROGRAMS

MEETING LIBRARY

Abstracts

Virtual Meeting

Educational Book

Meeting Slides

BOOKSTORE

CAREER CENTER

Back to the Top

Contact Us Privacy Policy Terms & Conditions American Society Of Clinical Oncology Conquer CancerFoundation Cancer.Net Journal Of Clinical Oncology Journal Of Oncology Practice

All content © 2015 American Society of Clinical Oncology. All rights reserved. Unauthorized reproduction is prohibited. Forpermission to re-use, please contact permissions@asco.org.

This online resource is supported by:

17/11/2015 Retrospective evaluation of tyrosine kinase inhibitor (TKI)-everolimus (eve) and/or TKI-eve-TKI sequences in metastatic renal cell carcinoma (mRCC): A Fr…

http://meetinglibrary.asco.org/content/123918-142 4/4